307 related articles for article (PubMed ID: 29908043)
1. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Hyseni A; Friedrich U; Chowdary P
J Thromb Haemost; 2018 Nov; 16(11):2184-2195. PubMed ID: 30137664
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
5. Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti-Tissue Factor Pathway Inhibitor Antibody, PF-06741086.
Parng C; Singh P; Pittman DD; Wright K; Leary B; Patel-Hett S; Rakhe S; Stejskal J; Peraza M; Dufield D; Murphy JE; Webster R
J Pharm Sci; 2018 Jul; 107(7):1995-2004. PubMed ID: 29571739
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic properties of a TFPI antibody.
Petersen LC
Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study.
Danto SI; Tsamandouras N; Reddy P; Gilbert S; Mancuso J; Page K; Peeva E; Vincent MS; Beebe JS
J Clin Pharmacol; 2024 May; 64(5):529-543. PubMed ID: 37772436
[TBL] [Abstract][Full Text] [Related]
10. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects.
Banfield C; Rudin D; Bhattacharya I; Goteti K; Li G; Hassan-Zahraee M; Brown LS; Hung KE; Pawlak S; Lepsy C
Br J Clin Pharmacol; 2020 Apr; 86(4):812-824. PubMed ID: 31758576
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa and VIIa inhibition by tissue factor pathway inhibitor is prevented by a monoclonal antibody to its Kunitz-1 domain.
Augustsson C; Svensson A; Kjaer B; Chao TY; Wenjuan X; Krogh BO; Breinholt J; Clausen JT; Hilden I; Petersen HH; Petersen LC
J Thromb Haemost; 2018 May; 16(5):893-904. PubMed ID: 29532595
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.
Dong JQ; Rossulek M; Somayaji VR; Baltrukonis D; Liang Y; Hudson K; Hernandez-Illas M; Calle RA
Br J Clin Pharmacol; 2015 Nov; 80(5):1051-63. PubMed ID: 25940675
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
16. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
19. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
Miyoshi I; Fujimoto Y; Yamada M; Abe S; Zhao Q; Cronenberger C; Togo K; Ishibashi T; Bednar MM; Kupiec JW; Binneman B
Int J Clin Pharmacol Ther; 2013 Dec; 51(12):911-23. PubMed ID: 24131736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]